Stada will pay $660m for a basket of 20 brands from Takeda to expand its consumer health portfolio in Russia and a number of strategically important CIS markets.
Stada Arzneimittel AG is beefing up its presence in Russia and the Commonwealth of Independent States (CIS) by snapping up a portfolio of OTC and prescription brands from Japan’s Takeda Pharmaceutical Co. Ltd. for $660m.
The deal comes shortly after Stada agreed to acquire Czech Republic-based Walmark to expand its footprint across Eastern Europe. (Also...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
